P L C SYSTEMS INC (PLCSF)

0.60
0.15 19.99
OTC
Prev Close 0.75
Open 0.80
Day Low/High 0.60 / 0.80
52 Wk Low/High 0.50 / 6.70
Volume 17.95K
Exchange OTC
Shares Outstanding 176.03M
Market Cap 897.70K
Div & Yield N.A. (N.A)

PLC Systems 2012 Financial Results Feature RenalGuard Sales Up 157% For The Fourth Quarter And 96% For The Full Year

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported financial results for the three and 12 months ended December 31, 2012.

PLC Systems Raises $4,040,000 In Equity Financing

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported that it has raised $4,040,000 in gross proceeds through the sale of...

PLC Systems Reports Third Quarter Financial Results

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today reported financial results for the three and nine months ended September 30,...

PLC Systems’ RenalGuard® To Be Featured In Contrast-Induced Kidney Injury Session At TCT 2012

PLC Systems Inc. (OTCBB: PLCSF), a medical device company focused on innovative technologies for the cardiac and vascular markets, today announced that its lead product, RenalGuard ®, will be featured during...

Investigator-Sponsored Study Of PLC's RenalGuard(R) Demonstrates Reduced Mortality And Fewer Adverse Events Than Alternatives

First Longer-Term Study Presented at ACC 2012 Reports Reduced Mortality and Reduced Adverse Events in Severe Renal Failure Patients Treated with RenalGuard compared to Hemofiltration and Sodium Bicarbonate

PLC Announces Approval To Distribute RenalGuard® In Brazil

Distributer Discomed Ready to Begin Sales and Marketing Immediately

MYTHOS Trial Of PLC's RenalGuard® Article Published In JACC -- Cardiovascular Interventions

Results Showed that Patients Treated with RenalGuard Developed CIN at a 74% Lower Rate than Those Treated With Overnight Hydration

PLC Systems Provides Update On Japanese Approval Process For RenalGuard®

First Step in Process to Secure Approval for Full RenalGuard® Study in Japan Completed

PLC Systems' RenalGuard® To Be Featured In Chronic Kidney Disease And Contrast Nephropathy Session At TCT 2011

PLC to Demonstrate RenalGuard, Host Investor Meeting and Support New Distributor, ACIST

PLC Systems Receives FDA Approval To Commence Pivotal Study Of RenalGuard In The U.S.

Modified design builds upon successful international studies

PLC Medical Systems CEO Presentation Now Available For On-demand Viewing At RetailInvestorConferences.com

Company invites individual and institutional investors to log-on to view presentation

PLC Systems Signs ACIST Medical Systems, To Distribute RenalGuard® In France And Germany

Agreement with Major Player Provides Powerful International Leverage

PLC Receives Two Additional U.S. Patents And First Japanese Patent For Its RenalGuard® Technology

Further solidifies intellectual property position for proprietary device aimed at large unmet medical need

REMEDIAL II Trial Of PLC's RenalGuard® Article Published In Circulation

Trial Demonstrated RenalGuard's Greater Efficacy than Current Standard of Care; Results Supported by Inclusion in Peer-Reviewed Journal

PLC Ramps Up For U.S. Clinical Trial Of RenalGuard®

Roxana Mehran, MD, Added as a Principal Investigator for Trial

PLC Medical Systems Adds Vice President Of Clinical Affairs

Susan Papalia, RN, BSN to Lead U.S. Pivotal Trial for RenalGuard®

PLC To Demonstrate RenalGuard® At EuroPCR 2011

Company to Hold Second Annual International Distributor Meeting as Part of Program

PLC Systems Reports Fourth Quarter 2009 Results

Second study interim results demonstrate RenalGuard® efficacy

PLC Provides Update On Financing Efforts And RenalGuard(R) Program

Signs distributors in China, Taiwan, Russia, Benelux, former SSR Nations and Portugal;